Merck has made a decisive move to solidify its respiratory drug portfolio, acquiring Verona Pharma for $10 billion in a deal centered around Ohtuvayre, a first-in-class treatment for chronic obstructive pulmonary disease (COPD). The transaction is among the most significant in biopharma this year, second only to Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular.
For Merck, the acquisition marks another bold stride in its recurring pattern of major deal-making every two years—previously acquiring Acceleron ($11.5B, 2021) and Prometheus Biosciences ($10.8B, 2023) to reinforce its late-stage pipeline. With blockbuster Keytruda expected to face patent expiry later this decade, Merck is actively reshaping its revenue base through strategic diversification.
CEO Rob Davis framed the transaction within Merck’s M&A “sweet spot” of $1 to $15 billion deals, saying the company remains open to larger acquisitions if the value proposition is right. He emphasized plans to launch 20 new growth assets over the coming years—most with blockbuster potential—while actively scouting in oncology, immunology, and cardiometabolic spaces.
Why Ohtuvayre Matters
Approved by the FDA in 2024, Ohtuvayre represents the first inhaled COPD therapy with a novel mechanism in over 20 years. The drug is a dual PDE3 and PDE4 inhibitor, allowing it to simultaneously expand airways and reduce inflammation. This dual-action approach sets it apart in a crowded market where most treatments either do one or the other.
Initial market response has been promising:
- Q1 2025 revenue: $71 million
- Quarter-on-quarter growth: 95%
- Prescriptions filled: 25,000 (up from 16,000 in 2024)
- 5,300 prescribers engaged in the U.S.
Despite lacking European approval, Ohtuvayre’s domestic performance demonstrates high clinical uptake and commercial traction—critical attributes that made it an attractive asset for Merck.
Strategic Fit with Merck’s Respiratory Platform
Merck is already familiar with pulmonary markets via Winrevair, its treatment for pulmonary arterial hypertension (PAH), acquired through Acceleron. Though Winrevair targets a rare condition, its prescriber base overlaps significantly with the COPD market. With approximately 14,500 prescribers in the U.S. focused on pulmonary care, Merck now has the infrastructure to rapidly expand Ohtuvayre’s reach.
According to Merck’s Human Health President Jannie Oosthuizen, the COPD market is expected to grow from $17 billion in 2025 to $27 billion by 2032. Merck’s scale and physician relationships could give it a significant first-mover advantage in shaping that expansion.
This deal reveals several strategic shifts in the global pharmaceutical landscape:
- Therapeutic Area Consolidation: Merck is doubling down on respiratory—an area traditionally seen as mature—with a belief in its long-term commercial upside, especially as chronic conditions become more prevalent.
- Blockbuster Pipeline Engineering: With Keytruda sunsetting, the company is clearly prioritizing assets that can replace multi-billion dollar revenue streams. Ohtuvayre’s novel mechanism and uptake profile suggest it can anchor Merck’s respiratory portfolio for the next decade.
- Prescriber Ecosystem Leverage: Merck is not just buying drugs—it’s buying access. By leveraging existing physician networks, Merck shortens the path from FDA approval to peak sales, a playbook that will likely become more common in pharma M&A.
- Buyout Timing: Merck’s timing—just after Ohtuvayre’s early commercial validation—is critical. This reduces risk compared to pre-approval bets, while still capturing the growth curve early enough to justify premium pricing.
Final Word
With this acquisition, Merck isn’t just filling a revenue gap left by Keytruda—it’s setting the tone for how big pharma thinks about the next generation of high-impact therapies. As the COPD market evolves and respiratory health becomes a broader public health priority, Ohtuvayre could be one of the defining therapies of the next era.
IMAGE: GETTY IMAGES
